Newsroom | 4146 results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia’s litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent est...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 128,750 common shares of the Company (the "Options"), with effective grant dates of June 2, 2025 and June 9, 2025, depending on the appli...

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data showcasing the impact of Viz ICH and Viz ICH Plus in optimizing care for patients with intracerebral hemorrhage (ICH). The study, “Optimizing Intracerebral Hemorrhage Management and Interhospital Transfer With Viz ICH Plus AI Technology,” highlights how AI-powered detection and quantification significantly reduced interhospital transfer (IHT) ti...

NEW YORK--(BUSINESS WIRE)--Colbeck Capital Management, a leading middle-market private credit firm focused on strategic lending, today announced its continued support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through sponsorship of its 2025 New York City Charity Poker Tournament. The tournament, to be held June 12 at The Prince George Ballroom, invites participants to “go all in” for the Children’s Tumor Foundation and features a cocktail reception followed by Texas Hold ‘E...

LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company’s presentation is scheduled for Monday, June 16 at 16:45 ET in Room 153B. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatmen...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company’s common stock to four new employees (the “Inducement Grants”) on June 5, 2025 (the “Grant Date”). The Induceme...

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals announced the launch of its new global website, as the company celebrates its 50th anniversary....

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast prese...

REDWOOD CITY, California--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), società in fase di sviluppo commerciale impegnata nella scoperta e nello sviluppo di farmaci per il trattamento di gravi patologie di natura endocrina, oncologica, metabolica e neurologica attraverso la modulazione degli effetti dell'ormone cortisolo, ha presentato i risultati dello studio DAZALS su dazucorilant in pazienti affetti da SLA in occasione della riunione annuale della European Network to Cur...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), een bedrijf in commerciële fase dat zich toelegt op het ontdekken en ontwikkelen van geneesmiddelen om ernstige endocrinologische, oncologische, metabolische en neurologische stoornissen te behandelen door de effecten van het hormoon cortisol te moduleren, presenteerde de resultaten van haar DAZALS-studie van dazucorilant bij patiënten met ALS tijdens de jaarlijkse bijeenkomst van de ENCALS (European Networ...